They tested their antiproliferative activity in human cancer cells lines of prostate (DU-145) and colon (HT-29) obtaining positive results, which suggests that STAT3 could be one of the many targets of this class of compounds and a new line to exploit. The gene discussed is STAT3; the disease is cancer.